Disclaimer: For laboratory research and informational use only
#The_power_of_Mind #success #leadership #Hiring #pharmacy #sales #learning #goals #leadership #Marketing #management #leadershipdevelopment #employeeengagement #leaders #people #leadershipfirst #leadershipfirstquotes #executivesandmanagement #inspiration #Health #Wellness #Nutrition GLP-1 Agonists Market to Reach $170.75B by 2033 -1 170.75 2033 : The global GLP-1 agonists market is expected to reach USD 170.75 billion in 2033 from USD 64.42 billion in 2025 at a CAGR of 13.0% during the forecast period
Learn more: #RealWorldEvidence #RWE #ObesityResearch #GLP1 #LifeSciences #HealthcareInnovation #DataDrivenHealthcare To view or add a comment, sign in Looking forward to reading the findings of this long-awaited study
Both medicines contain semaglutide but are formulated and FDA-approved for specific purposes Ozempic for diabetes management and Wegovy for weight management
GLP-1RAs act on multiple pathophysiologies of type 2 diabetes (at least six [Pancreas (a and b cells), liver, muscle, brain, incretin] out of eight)
It is typically administered once daily by injection to help control fasting blood sugar levels
